OPKO Health, Inc. (OPK)
Stock Price Chart
Key Info
| Market Cap | 3.71B |
| Revenue (ttm) | 965.79M |
| Net Income (ttm) | -199.79M |
| Shares Out | 669.83M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 7, 2020 |
| Last Price | $5.54 |
| Previous Close | $5.66 |
| Change ($) | -0.13 |
| Change (%) | -2.21% |
| Day's Open | 5.65 |
| Day's Range | 5.54 - 5.76 |
| Day's Volume | 6,015,981 |
| 52-Week Range | 1.12 - 6.47 |
More Stats
| Market Cap | 3.71B |
| Enterprise Value | 3.96B |
| Earnings Date (est) | Nov 4, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 669.83M |
| Float | 382.08M |
| EPS (basic) | -0.33 |
| EPS (diluted) | -0.32 |
| FCF / Share | -0.24 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 129.49M |
| Short Ratio | 9.49 |
| Short % of Float | 34.26% |
| Beta | 2.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 3.84 |
| PB Ratio | 2.23 |
| Revenue | 965.79M |
| Operating Income | -165.06M |
| Net Income | -199.79M |
| Free Cash Flow | -150.73M |
| Net Cash | -248.37M |
| Net Cash / Share | -0.37 |
| Gross Margin | 27.43% |
| Operating Margin | -17.09% |
| Profit Margin | -20.70% |
| FCF Margin | -15.61% |
| ROA | -1.92% |
| ROE | -12.12% |
| ROIC | -15.70% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 902 | 990 | 966 | 1,117 | 492 | 91.13 | 96.53 | 47.04 | 27.98 | 28.49 |
| Revenue Growth | -8.92% | 2.51% | -13.56% | 127.25% | 439.63% | -5.6% | 105.19% | 68.14% | -1.81% | - |
| Gross Profit | 329 | 386 | 346 | 506 | 256 | 43.12 | 47.67 | 19.17 | 10.74 | 15.00 |
| Operating Income | -274 | -171 | -276 | -96.55 | -98.48 | -146 | -79.63 | -37.27 | -23.19 | -11.14 |
| Net Income | -315 | -153 | -305 | -48.36 | -30.03 | -172 | -114 | -29.05 | -1.28 | -18.93 |
| Shares Outstanding | 595 | 563 | 559 | 551 | 488 | 422 | 355 | 296 | 281 | 255 |
| Earnings Per Share | -0.53 | -0.27 | -0.55 | -0.10 | -0.06 | -0.41 | -0.32 | -0.11 | -0.01 | -0.08 |
| Operating Cash Flow | -173 | -109 | -92.08 | 32.05 | 164 | -90.38 | -55.65 | -25.42 | -18.50 | -18.71 |
| Capital Expenditures | -12.07 | -26.64 | -39.25 | -17.15 | -10.85 | -4.73 | -3.33 | -1.47 | -1.95 | -0.77 |
| Free Cash Flow | -185 | -136 | -131 | 14.90 | 153 | -95.11 | -58.98 | -26.89 | -20.45 | -19.49 |
| Cash & Equivalents | 85.45 | 96.47 | 91.50 | 169 | 194 | 96.91 | 186 | 27.36 | 71.52 | 18.02 |
| Total Debt | 261 | 94.71 | 41.09 | 55.68 | 60.45 | 145 | 224 | 17.53 | 8.76 | 14.69 |
| Net Cash / Debt | -175 | 1.76 | 50.41 | 113 | 133 | -48.00 | -38.68 | 9.84 | 62.76 | 3.33 |
| Assets | 2,309 | 2,451 | 2,590 | 2,767 | 2,799 | 1,268 | 1,392 | 290 | 229 | 77.85 |
| Liabilities | 695 | 660 | 746 | 675 | 819 | 432 | 519 | 86.55 | 44.22 | 28.67 |
| Book Value | 1,615 | 1,791 | 1,844 | 2,092 | 1,980 | 842 | 876 | 179 | 161 | 23.05 |
Company Profile
Company Details
| Full Name | OPKO Health, Inc. |
| Country | United States |
| Employees | 6,096 |
| CEO | Phillip Frost |
Stock Information
| Ticker Symbol | OPK |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Unique Identifier | NASDAQ: OPK |
| IPO Date | November 2, 1995 |
Description
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase IIb trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.